Received Mar 23, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | Unknown | PO / MO |
The patient left Vivotif vaccine at room temperature for about a week and took second and third dose; The patient left Vivotif vaccine at room temperature for about a week and took second and third dose; Case reference number US-BN-2024-002327 is a spontaneous case initially received from a pharmacist via agency (reference number USBAV24-1925) on 09-Aug-2024 and concerns a female patient of unknown age. The patient's medical history and concomitant medication details were not provided. On unspecified date, reported as four to six days ago, the patient took the first dose of Vivotif vaccine (batch number: unknown), at a dose of capsule, orally for an unknown indication. As reported, the first dose of Vivotif was refrigerated but then the patient left it at room temperature for about a week (explicitly coded as 'Product storage error'). On unspecified date, unknown amount of time after first dose of Vivotif, the patient took the second dose of Vivotif vaccine batch number: unknown), at a dose of capsule, orally (explicitly coded as 'Product administration error'). On unspecified date, unknown amount of time after second dose of Vivotif, the patient took the third dose of Vivotif vaccine batch number: unknown), at a dose of capsule, orally. As reported, the patient realized that Vivotif vaccine should have been refrigerated (explicitly coded as 'Product administration error'). As reported, the patient has not taken fourth dose yet. At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. Non-significant follow-up was downloaded from VAERS on 09-May-2025 included new reference number. Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20240809-eac2a8 to US-BAVARIAN NORDIC A/S-US-BN-2024-002327, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: A female patient stored Vivotif at room temperature for about a week, and then received her second and third doses. This is considered product storage error and product administration error, which are listed special situations per convention. No associated adverse events were reported. Patient's medical history details were not available. Product storage and administration error are not related to Vivotif, but to human error. The case is non-serious.; Sender's Comments: A female patient stored Vivotif at room temperature for about a week, and then received her second and third doses. This is considered product storage error and product administration error, which are listed special situations per convention. No associated adverse events were reported. Patient's medical history details were not available. Product storage and administration error are not related to Vivotif, but to human error. The case is non-serious. USBAV24-1925:
Comments: None